Guizhou Bailing Group Pharmaceutical Co Ltd Net Assets

Latest as of March 2026: CN¥3.20 Billion CNY ≈ $468.57 Million USD

Guizhou Bailing Group Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has net assets worth CN¥3.20 Billion CNY (≈ $468.57 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.95 Billion ≈ $871.40 Million USD) and total liabilities (CN¥2.75 Billion ≈ $402.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Guizhou Bailing Group Pharmaceutical Co annual equity growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥3.20 Billion
% of Total Assets	53.77%
Annual Growth Rate	17.19%
5-Year Change	-19.83%
10-Year Change	3.57%
Growth Volatility	89.27

Net Assets of Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)

Net assets of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Guizhou Bailing Group Pharmaceutical Co to measure how much of total assets are equity-financed.

Annual Net Assets for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)

The table below shows the annual net assets of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025. For live market cap and overall valuation, see Guizhou Bailing Group Pharmaceutical Co stock valuation.

Year	Net Assets	Change
2025-12-31	CN¥3.17 Billion ≈ $464.57 Million	-0.76%
2024-12-31	CN¥3.20 Billion ≈ $468.14 Million	-9.30%
2023-12-31	CN¥3.53 Billion ≈ $516.15 Million	-11.75%
2022-12-31	CN¥4.00 Billion ≈ $584.87 Million	+0.93%
2021-12-31	CN¥3.96 Billion ≈ $579.50 Million	+1.02%
2020-12-31	CN¥3.92 Billion ≈ $573.66 Million	-5.22%
2019-12-31	CN¥4.14 Billion ≈ $605.25 Million	+5.39%
2018-12-31	CN¥3.92 Billion ≈ $574.31 Million	+13.20%
2017-12-31	CN¥3.47 Billion ≈ $507.36 Million	+13.11%
2016-12-31	CN¥3.07 Billion ≈ $448.56 Million	+14.34%
2015-12-31	CN¥2.68 Billion ≈ $392.31 Million	+14.19%
2014-12-31	CN¥2.35 Billion ≈ $343.57 Million	+10.37%
2013-12-31	CN¥2.13 Billion ≈ $311.30 Million	+4.15%
2012-12-31	CN¥2.04 Billion ≈ $298.89 Million	+5.27%
2011-12-31	CN¥1.94 Billion ≈ $283.94 Million	+5.05%
2010-12-31	CN¥1.85 Billion ≈ $270.28 Million	+393.30%
2009-12-31	CN¥374.42 Million ≈ $54.79 Million	+42.50%
2008-12-31	CN¥262.75 Million ≈ $38.45 Million	+43.83%
2007-12-31	CN¥182.68 Million ≈ $26.73 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guizhou Bailing Group Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 5005.0% over the analyzed period, indicating profitable operations and earnings retention.

Guizhou Bailing Group Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)

Guizhou Bailing Group Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Retained Earnings	CN¥1.49 Billion	47.21%
Other Components	CN¥1.67 Billion	52.79%
Total Equity	CN¥3.16 Billion	100.00%

Guizhou Bailing Group Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guizhou Bailing Group Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Prodea Real Estate Investment Co. AT:PRODEA	$908.05 Million
Guan Chong Bhd KLSE:5102	$908.24 Million
Oppenheimer Holdings Inc NYSE:OPY	$908.89 Million
Strait Innovation Internet Co Ltd SHE:300300	$909.45 Million
Elemental Royalty Corporation NASDAQ:ELE	$908.00 Million
Hotel Shilla KO:008770	$907.95 Million
Cobram Estate Olives Ltd AU:CBO	$907.92 Million
Drägerwerk AG & Co. KGaA XETRA:DRW8	$907.49 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guizhou Bailing Group Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,181,166,740 to 3,155,519,418, a change of -25,647,322 (-0.8%).
Net loss of 104,366,045 reduced equity.
Dividend payments of 62,476,806 reduced retained earnings.
Other factors increased equity by 141,195,529.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-104.37 Million	-3.31%
Dividends Paid	CN¥62.48 Million	-1.98%
Other Changes	CN¥141.20 Million	+4.47%
Total Change	CN¥-	-0.81%

Book Value vs Market Value Analysis

This analysis compares Guizhou Bailing Group Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.97x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 25.84x to 1.97x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2007-12-31	CN¥0.17	CN¥4.44	x
2008-12-31	CN¥0.25	CN¥4.44	x
2009-12-31	CN¥0.57	CN¥4.44	x
2010-12-31	CN¥1.44	CN¥4.44	x
2011-12-31	CN¥1.35	CN¥4.44	x
2012-12-31	CN¥1.43	CN¥4.44	x
2013-12-31	CN¥1.48	CN¥4.44	x
2014-12-31	CN¥1.65	CN¥4.44	x
2015-12-31	CN¥1.87	CN¥4.44	x
2016-12-31	CN¥2.13	CN¥4.44	x
2017-12-31	CN¥2.40	CN¥4.44	x
2018-12-31	CN¥2.68	CN¥4.44	x
2019-12-31	CN¥2.87	CN¥4.44	x
2020-12-31	CN¥2.81	CN¥4.44	x
2021-12-31	CN¥2.66	CN¥4.44	x
2022-12-31	CN¥2.88	CN¥4.44	x
2023-12-31	CN¥2.54	CN¥4.44	x
2024-12-31	CN¥1.89	CN¥4.44	x
2025-12-31	CN¥2.26	CN¥4.44	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guizhou Bailing Group Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -3.31%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -3.42%
• Asset Turnover: 0.49x
• Equity Multiplier: 1.96x
Recent ROE (-3.31%) is below the historical average (11.64%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	39.41%	16.11%	0.90x	2.73x	CN¥53.66 Million
2008	30.56%	13.35%	1.03x	2.22x	CN¥54.02 Million
2009	29.82%	15.35%	0.89x	2.19x	CN¥74.22 Million
2010	8.57%	18.32%	0.31x	1.52x	CN¥-26.50 Million
2011	10.89%	18.30%	0.38x	1.58x	CN¥16.95 Million
2012	10.95%	16.21%	0.42x	1.60x	CN¥19.31 Million
2013	12.80%	19.18%	0.40x	1.65x	CN¥59.02 Million
2014	13.37%	19.72%	0.44x	1.54x	CN¥78.30 Million
2015	15.54%	21.66%	0.49x	1.45x	CN¥146.70 Million
2016	15.96%	21.78%	0.52x	1.40x	CN¥180.17 Million
2017	15.39%	20.30%	0.54x	1.41x	CN¥184.16 Million
2018	14.55%	17.96%	0.52x	1.54x	CN¥176.22 Million
2019	6.98%	9.92%	0.40x	1.74x	CN¥-122.44 Million
2020	3.91%	4.93%	0.44x	1.81x	CN¥-237.01 Million
2021	3.01%	3.81%	0.48x	1.65x	CN¥-275.65 Million
2022	3.47%	3.91%	0.51x	1.73x	CN¥-260.99 Million
2023	-11.80%	-9.72%	0.58x	2.09x	CN¥-765.75 Million
2024	1.06%	0.88%	0.54x	2.24x	CN¥-284.49 Million
2025	-3.31%	-3.42%	0.49x	1.96x	CN¥-419.92 Million

Industry Comparison

This section compares Guizhou Bailing Group Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,632,405,673
Average return on equity (ROE) among peers: 7.53%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guizhou Bailing Group Pharmaceutical Co Ltd (002424)	CN¥3.20 Billion	39.41%	0.86x	$908.04 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.97 Billion	4.04%	0.54x	$488.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$560.87 Million	4.60%	0.22x	$360.39 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.02 Billion	12.46%	0.13x	$4.73 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.04 Billion	4.29%	0.46x	$2.58 Billion
Wedge Industrial Co Ltd (000534)	$0.00	0.00%	0.00x	$1.20 Billion
Yunnan Baiyao Group Co Ltd (000538)	$18.14 Billion	17.33%	0.53x	$14.52 Billion
Hainan Haiyao Co Ltd (000566)	$491.82 Million	6.71%	1.19x	$755.58 Million
Tus Pharmaceutical Group Co Ltd (000590)	$280.91 Million	1.46%	1.58x	$272.98 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$5.57 Billion	7.36%	1.59x	$920.83 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$7.25 Billion	17.08%	0.09x	$3.02 Billion

About Guizhou Bailing Group Pharmaceutical Co Ltd

SHE:002424 China Drug Manufacturers - Specialty & Generic

Market Cap

$908.04 Million

CN¥6.21 Billion CNY

Market Cap Rank

#8960 Global

#2110 in China

Share Price

CN¥4.44

Change (1 day)

-0.89%

52-Week Range

CN¥4.09 - CN¥6.18

All Time High

CN¥28.52